Rathbones Group PLC raised its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 17.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,890 shares of the medical instruments supplier’s stock after purchasing an additional 2,719 shares during the period. Rathbones Group PLC’s holdings in Becton, Dickinson and Company were worth $3,202,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in BDX. BlackRock Inc. bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at approximately $3,721,533,000. Bank of America Corp DE acquired a new position in Becton, Dickinson and Company in the second quarter worth approximately $474,993,000. First Eagle Investment Management LLC raised its position in Becton, Dickinson and Company by 15.8% during the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after acquiring an additional 1,887,224 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Becton, Dickinson and Company during the second quarter valued at approximately $247,372,000. Finally, Deutsche Bank AG bought a new position in Becton, Dickinson and Company during the second quarter valued at approximately $204,226,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of analysts have issued reports on BDX shares. TD Cowen lifted their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Jefferies Financial Group restated a “buy” rating and set a $242.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, November 5th. Zacks Research downgraded shares of Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price objective for the company. Finally, Wells Fargo & Company lifted their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and an average price target of $197.47.
Get Our Latest Stock Analysis on BDX
Insider Buying and Selling
In other news, CEO Thomas Polen, Jr. sold 2,993 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $210.00, for a total value of $628,530.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $23,134,230. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 3,310 shares of company stock worth $688,650. Insiders own 0.40% of the company’s stock.
Becton, Dickinson and Company Stock Performance
Shares of NYSE BDX opened at $212.19 on Friday. The business’s 50-day simple moving average is $194.40 and its 200-day simple moving average is $170.85. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.54 and a current ratio of 0.87. Becton, Dickinson and Company has a 52 week low of $140.11 and a 52 week high of $220.36. The firm has a market cap of $58.47 billion, a price-to-earnings ratio of 51.25, a P/E/G ratio of 3.56 and a beta of 0.22.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.08. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The firm had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.11 billion. During the same period in the previous year, the company earned $3.96 EPS. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. As a group, equities research analysts expect that Becton, Dickinson and Company will post 13.21 earnings per share for the current fiscal year.
Becton, Dickinson and Company Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be given a $1.06 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Thursday, December 10th. Becton, Dickinson and Company’s payout ratio is 101.45%.
Becton, Dickinson and Company announced that its board has initiated a share buyback plan on Thursday, November 5th that permits the company to repurchase 10,000,000 shares. This buyback authorization permits the medical instruments supplier to repurchase up to 3.6% of its shares through open market purchases. Stock buyback plans are usually a sign that the company’s board believes its stock is undervalued.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
Featured Stories
- Five stocks we like better than Becton, Dickinson and Company
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
